{"schema_version":"secwatch.filing_event.v1","accession":"0001404644-26-000044","form_type":"8-K","ticker":"NGNE","cik":"0001404644","company_name":"Neurogene Inc.","filed_at":"2026-06-08T11:32:53+00:00","discovered_at":"2026-06-08T11:35:00.297499+00:00","generated_at":"2026-06-08T11:35:53.854625+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Neurogene completes dosing in NGN-401 Rett trial; no HLH, topline expected 2H 2027","bullets":["Dosed 25 participants in Embolden trial (target 20, ITT up to 24) due to strong demand from Rett community.","NGN-401 generally well-tolerated; no HLH cases at 1E15 vg dose across Phase 1/2 and Embolden (n=35).","Topline data from registrational trial expected in 2H 2027; BLA submission planned.","Interim Phase 1/2 data with ≥12-month follow-up for all 10 participants expected mid-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001404644-26-000044","json":"https://secwatch.observer/filing/0001404644-26-000044.json","markdown":"https://secwatch.observer/filing/0001404644-26-000044.md","text":"https://secwatch.observer/filing/0001404644-26-000044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404644/000140464426000044/0001404644-26-000044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404644/000140464426000044/ngne-20260608.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T11:35:53.854625+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}